Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

The tremendous clinical success of checkpoint blockers illustrates the potential of
reestablishing latent immunosurveillance for cancer therapy. Although largely neglected in …

Emerging evidence suggests that the clinical success of conventional chemotherapy is not
solely attributed to tumor cell toxicity, but also results from the restoration of …

Background Regorafenib and other multikinase inhibitors may enhance antitumor efficacy of
anti-program cell death-1 (anti-PD1) therapy in hepatocellular carcinoma (HCC). Its …

Accumulating preclinical and clinical evidence indicates that the success of several
anticancer agents—including some conventional chemotherapeutics, targeted anticancer …

In situ-forming thermosensitive hydrogels based on poly (ethylene glycol)-poly (γ-ethyl-l-
glutamate) diblock copolymers (mPEG-b-PELG) were prepared for the co-delivery of …

Multikinase inhibitors with antiangiogenic properties used to be standard therapy for patients
with advanced hepatocellular carcinoma (HCC). Recently, several antiangiogenic agents …

The tumor microenvironment is highly heterogeneous. It is composed of a diverse array of
immune cells that are recruited continuously into lesions. They are guided into the tumor …

The activating receptor NKG2D and its ligands are recognized as a potent immune axis that
controls tumor growth and microbial infections. With regards to cancer surveillance, various …

The combination of atezolizumab plus bevacizumab has demonstrated marked superiority to
sorafenib, the current standard of care for unresectable hepatocellular carcinoma (HCC) …